Propagenix is an R&D-stage cell therapy company engaged in the development and commercialization of technology which initially originated from the laboratory of Dr. Richard Schlegel of Georgetown University. The company was founded in 2014 and is located in the I-270 corridor of Montgomery County, Maryland. The company is dedicated to continuing to develop Propagenix technology for a wide range of applications in basic and translational biomedical research. Our vision is to enable the creation of new and more effective drugs, personalized diagnostics and cell therapies that will enhance human healthcare. The team has created a culture that places high value and thrives on scientific excellence, innovation, open and honest communication, a collaborative attitude, and a fast-paced work environment.